Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ranibizumab PRN monotherapy for macular edema secondary to central retinal vein occlusion
2011-002350-31Phase 4Completed
- Sponsor
- Novartis
- Start
- Nov 2011
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of ranibizumab in central retinal vein occlusion (CRVO) and central retinal vein occlusion with macular edema, sponsored by Novartis. Primary endpoint: Mean change in BCVA at Month 12. Started Nov 2011; status: completed.
02
Drugs
ranibizumab
03
Conditions
central retinal vein occlusion (CRVO)central retinal vein occlusion with macular edema
Beyond the preview
Go deeper on 2011-002350-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-002350-31.